SAN DIEGO, Nov. 18, 2014 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology
company focused on delivering breakthrough 3D bioprinting
technology, today announced the full commercial release of the
exVive3DTM Human Liver Tissue for preclinical drug
discovery testing. Initially, clients will be able to access
the technology through Organovo's contract research services
program. This model is intended to provide human-specific data to
aid in the prediction of liver tissue toxicity or ADME outcomes in
later stage preclinical drug discovery programs.
Organovo's exVive3D Liver Models are bioprinted, living 3D human
liver tissues consisting of primary human hepatocytes, stellate,
and endothelial cell types, which are found in native human liver.
The exVive3D Liver Models are created using Organovo's proprietary
3D bioprinting technology that builds functional living tissues
containing precise and reproducible architecture. The tissues are
functional and stable for at least 42 days, which enables
assessment of drug effects over study durations that well beyond
those offered by industry-standard 2D liver cell culture
systems.
Organovo has previously shown that exVive3D Liver Models produce
important liver proteins including albumin, fibrinogen and
transferrin, synthesize cholesterol, and possess inducible
cytochrome P450 enzymatic activities, including CYP 1A2 and CYP
3A4. The exVive 3D Liver has successfully differentiated between
structurally related compounds with known toxic and non-toxic
profiles in human beings, and the model has also been employed
successfully in the detection of metabolites at extended time
points in vitro. Importantly, the configuration of the
bioprinted liver tissues enables both biochemical and histologic
data to be collected so that a customer can investigate compound
responses at multiple levels.
The durability and functionality of the 3D liver
product enable the assessment of the effects of low dose or
repeated dosing regimens across a spectrum of biochemical,
molecular, and histologic end points. All testing will be
performed at Organovo's facility by the Company's laboratory
services tissue experts.
For more information or to discuss specific study requirements,
clients can contact us at sales@organovo.com, or visit our website
at www.organovo.com.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for medical research and therapeutic applications. The
Company is collaborating with pharmaceutical and academic partners
to develop human biological disease models in three dimensions.
These 3D human tissues have the potential to accelerate the drug
discovery process, enabling treatments to be developed faster and
at lower cost. The company plans to market its first product of a
planned portfolio offering, a 3D Human Liver Tissue for use in
Toxicology and other preclinical drug testing prior to the end of
2014, and remains on track to bring this breakthrough technology to
customers. In addition to numerous scientific publications,
the Company's technology has been featured in The Wall Street
Journal, Time Magazine, The Economist, and numerous others.
Organovo is changing the shape of medical research and practice.
Learn more at www.organovo.com
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations, but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the market acceptance of the Company's
products; and the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in our filings with the SEC, including our
annual report on Form 10-K filed with the SEC on June 10, 2014 and its report on Form 10-Q filed
with the SEC on November 7, 2014, as
well as our other filings with the SEC. You should not place undue
reliance on these forward-looking statements, which speak only as
of the date that they were made. These cautionary statements should
be considered with any written or oral forward-looking statements
that we may issue in the future. Except as required by applicable
law, including the securities laws of the
United States, we do not intend to update any of the
forward-looking statements to conform these statements to reflect
actual results, later events or circumstances or to reflect the
occurrence of unanticipated events.
SOURCE Organovo Holdings, Inc.